



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Girinimbine

Cat. No.:	HY-N9488
CAS No.:	23095-44-5
Molecular Formula:	C ₁₈ H ₁₇ NO
Molecular Weight:	263.33
Target:	Apoptosis; Bacterial; Parasite
Pathway:	Apoptosis; Anti-infection
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



BIOLOGICAL ACTIVITY

Description

Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities^[1]^[2]^[3].

In Vitro

Girinimbine (1-400 μM; 24-72 h) decreases the viability of HepG2 cells in 24, 48 and 72 h with IC₅₀ values of 61 μM, 56 μM, and 40 μM respectively. Girinimbine (10-100 μM; 24-48 h) increase of LDH leakage in both concentration- and time-dependent manner in HepG2 cells^[1].

Girinimbine (56 μM; 24-48 h) treatment results in DNA fragmentation and elevates levels of caspase-3 in HepG2 cells^[1]. HepG2 cells^[1].

Girinimbine (56 μM; 12-48 h) treatment also displays a time-dependent accumulation of the Sub-G0/G1 peak (hypodiploid) and caused G0/G1-phase arrest^[1].

Girinimbine shows a potent antitrypanosomal activity with an IC₅₀ value of 10.16 μg/mL^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HepG2 cells
Concentration:	1 μM, 10 μM, 50 μM, 100 μM, 200 μM
Incubation Time:	24 h, 48 h and 72 h
Result:	Inhibited the proliferation of HepG2 cells in vitro in a dose- and time-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	HepG2 cells
Concentration:	56 μM
Incubation Time:	24 h, 48 h
Result:	Showed typical morphological features of apoptosis.

Cell Cycle Analysis^[1]

	Cell Line:	HepG2 cells
	Concentration:	56 μ M
	Incubation Time:	12 h, 24 h, 48 h
	Result:	Induced G0/G1-phase arrest in HepG2 cells.
In Vivo	Girinimbine (10-100 mg/kg; orally gavage; once) pretreatment helps limit total leukocyte migration, and reduced pro-inflammatory cytokine (IL-1 β , TNF- α) levels in the peritoneal fluid ^[2] . In vivo in zebrafish embryos, Girinimbine (20 μ g/mL; 24 hours) shows significant distribution of apoptotic cells in embryos ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male ICR mice (25-35 g) treated with carrageenan ^[2]
	Dosage:	10 mg/kg, 30 mg/kg, and 100 mg/kg
	Administration:	Orally gavage; once
	Result:	Helped limit total leukocyte migration, and reduced pro-inflammatory cytokine levels in the peritoneal fluid.

REFERENCES

- [1]. Suvitha Syam, et al. The growth suppressing effects of girinimbine on HepG2 involve induction of apoptosis and cell cycle arrest. *Molecules*. 2011 Aug 23;16(8):7155-70.
- [2]. Venoos Iman, et al. Anticancer and anti-inflammatory activities of girinimbine isolated from *Murraya koenigii*. *Drug Des Devel Ther*. 2016 Dec 28;11:103-121.
- [3]. H O Dyary, et al. Antitrypanosomal and cytotoxic activities of botanical extracts from *Murraya koenigii* (L.) and *Alpinia mutica* Roxb. *Trop Biomed*. 2019 Mar 1;36(1):94-102.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA